Author

Donata Sartori

Observed names: D Sartori, D. Sartori, Sartori, Donata

Observed institutions: University of Trieste, Sanofi (France), Hospital Clínico Universitario de Valencia, Ospedale di Mirano, Azienda Ospedaliera Universitaria Policlinico "Paolo Giaccone" di Palermo, Centro de Investigación Biomédica en Red de Cáncer

ORCID: 0009-0001-7717-9251

Observed ORCID: 0009-0001-7717-9251

OpenAlex ID: A5003661852

Clinical Outcomes of Castration-resistant Prostate Cancer Treatments Administered as Third or Fourth Line Following Failure of Docetaxel and Other Second-line Treatment: Results of an Italian Multicentre Study

2014 · Orazio Caffo, Ugo De Giorgi, et al. · European Urology · 83

Oral Selinexor as Maintenance Therapy After First-Line Chemotherapy for Advanced or Recurrent Endometrial Cancer

2023 · Ignace Vergote, Jose Alejandro Pérez-Fidalgo, et al. · Journal of Clinical Oncology · 78

Significance of PD-L1 in Metastatic Urothelial Carcinoma Treated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis

2024 · Brigida Anna Maiorano, Massimo Di Maio, et al. · JAMA Network Open · 61

Correlation between genetic and biological aspects in primary non-metastatic breast cancers and corresponding synchronous axillary lymph node metastasis

2006 · Mario R. D’Andrea, Maria R. Limiti, et al. · Breast Cancer Research and Treatment · 58

Real-world effectiveness comparison of first-line palbociclib, ribociclib or abemaciclib plus endocrine therapy in advanced HR-positive/HER2-negative BC patients: results from the multicenter PALMARES-2 study

2025 · L. Provenzano, M.V. Dieci, et al. · Annals of Oncology · 51

PDF

Symptomatic COVID-19 in advanced-cancer patients treated with immune-checkpoint inhibitors: prospective analysis from a multicentre observational trial by FICOG

2020 · Melissa Bersanelli, Diana Giannarelli, et al. · Therapeutic Advances in Medical Oncology · 25

Impact of influenza vaccination on survival of patients with advanced cancer receiving immune checkpoint inhibitors (INVIDIa-2): final results of the multicentre, prospective, observational study

2023 · Melissa Bersanelli, Elena Verzoni, et al. · EClinicalMedicine · 24

PDF

The Impact of Progenitor Enrichment, Serum, and Cytokines on the Ex Vivo Expansion of Mobilized Peripheral Blood Stem Cells: A Controlled Trial

2003 · Elena Balducci, Giuseppe Azzarello, et al. · Stem Cells · 23

Efficacy and safety of Everolimus and Exemestane in hormone-receptor positive (HR+) human-epidermal-growth-factor negative (HER2−) advanced breast cancer patients: New insights beyond clinical trials. The EVA study

2017 · M.E. Cazzaniga, M. Airoldi, et al. · The Breast · 22

Docetaxel and prednisone with or without enzalutamide as first-line treatment in patients with metastatic castration-resistant prostate cancer: CHEIRON, a randomised phase II trial

2021 · Orazio Caffo, Cinzia Ortega, et al. · European Journal of Cancer · 18

Serum neopterin levels in haematological malignancies.

1993 · A Caenazzo, F Pietrogrande, et al. · PubMed · 13

Primary breast lymphoma.

1998 · F Vianello, D Sgarabotto, et al. · PubMed · 12

Everolimus Plus Exemestane in Advanced Breast Cancer: Safety Results of the BALLET Study on Patients Previously Treated Without and with Chemotherapy in the Metastatic Setting

2017 · Daniele Generali, Filippo Montemurro, et al. · The Oncologist · 11

PDF

Vasomotor symptoms and management of women undergoing treatment for breast cancer: literature review with focus on the therapeutic potential of cytoplasmic pollen extract

2023 · Stefano Lello, Ida Paris, et al. · Gynecological Endocrinology · 10

PDF

Comparison of antitumor efficacy of first-line palbociclib, ribociclib, or abemaciclib in patients with HR+/HER2- aBC: Results of the multicenter, real-world, Italian study PALMARES-2.

2024 · Claudio Vernieri, Leonardo Provenzano, et al. · Journal of Clinical Oncology · 9

A New Genetic Risk Score to Predict the Outcome of Locally Advanced or Metastatic Breast Cancer Patients Treated With First-Line Exemestane: Results From a Prospective Study

2018 · Sara Gagno, Mario Rosario D’Andrea, et al. · Clinical Breast Cancer · 9

PDF

Joint survey by AIMN, AIOM, AIRO, SIU, SIUrO, and Meet-URO about the use of PSMA PET imaging in prostate cancer in Italy: technical aspects and primary staging setting

2025 · Matteo Bauckneht, Laura Evangelista, et al. · Clinical and Translational Imaging · 8

PDF

Real-World Treatment with Nivolumab or Cabozantinib for Metastatic Renal Cell Carcinoma (mRCC) in the Veneto Region of Italy: Results of AMOUR Study

2022 · Marco Maruzzo, Francesco Pierantoni, et al. · Targeted Oncology · 7

PDF

Real-world experience of abiraterone acetate plus prednisone in chemotherapy-naive patients with metastatic castration-resistant prostate cancer: long-term results of the prospective ABItude study

2022 · G. Procopio, V.E. Chiuri, et al. · ESMO Open · 7

PDF

Effects of abiraterone acetate plus prednisone on bone turnover markers in chemotherapy-naïve mCRPC patients after ADT failure: A prospective analysis of the italian real-world study ABITUDE

2020 · Daniele Santini, Saverio Cinieri, et al. · Journal of bone oncology · 7

PDF

A multicentric phase II randomized trial of docetaxel (D) plus enzalutamide (E) versus docetaxel (D) as first-line chemotherapy for patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): CHEIRON study.

2019 · Orazio Caffo, Erica Palesandro, et al. · Journal of Clinical Oncology · 7

Assessing the effectiveness and safety of lenvatinib and everolimus in advanced renal cell carcinoma: insights from the RELIEVE study’s analysis of heavily pretreated patients

2024 · Sebastiano Buti, Alessandro Olivari, et al. · Therapeutic Advances in Urology · 5

PDF

Salvage Therapy with Capecitabine Plus Weekly Paclitaxel in Heavily Pretreated Advanced Breast Cancer: A Multicenter Phase II Study

2005 · Mario Bari, Mario Rosario D???Andrea, et al. · American Journal of Cancer · 5

Everolimus (EVE) and exemestane (EXE) in patients with advanced breast cancer aged ≥ 65 years: new lessons for clinical practice from the EVA study

2018 · Marina Cazzaniga, The EVA Study Group, et al. · Oncotarget · 4

PDF

Joint survey by AIMN, AIOM, AIRO, SIU, SIUrO, and Meet-URO about the use of PSMA PET imaging in prostate cancer in Italy: PSA persistence, biochemical recurrence, hormone-sensitive and castration-resistant metastatic settings

2026 · Matteo Bauckneht, Laura Evangelista, et al. · Clinical and Translational Imaging · 3

PDF

Works count: 88

Citation count: 569

H-index: 12

I10-index: 14